New drug for mdr tb

A very timely and important topic!

Multidrug-resistant tuberculosis (MDR-TB) is a significant global health threat, and the development of new drugs to combat it is crucial. Here are some recent updates on new drugs and treatments for MDR-TB:

1. Bedaquiline (Sirturo): Approved in 2012, bedaquiline is the first new TB drug in over 40 years. It's a diarylquinoline that works by inhibiting the bacterial enzyme ATP synthase, which is essential for the survival of M. tuberculosis. Bedaquiline has been shown to improve treatment outcomes for MDR-TB patients.
2. Delamanid (Deltyba): Approved in 2014, delamanid is a nitroimidazole that targets the bacterial enzyme DNA polymerase. It's used in combination with other drugs to treat MDR-TB. Delamanid has been shown to improve treatment outcomes and reduce the risk of treatment failure.
3. Linezolid (Zyvox): While not specifically approved for MDR-TB, linezolid is an oxazolidinone that has been used off-label to treat MDR-TB. It works by inhibiting protein synthesis in bacteria. Linezolid has been shown to be effective in treating MDR-TB, particularly in combination with other drugs.
4. Pretomanid (PA-824): Pretomanid is a nitroimidazole that's being developed by the non-profit organization TB Alliance. It's in Phase III clinical trials for the treatment of MDR-TB and has shown promising results in combination with other drugs.
5. Otsittazosin (PA-824): Otsittazosin is another nitroimidazole being developed by the TB Alliance. It's in Phase II clinical trials for the treatment of MDR-TB and has shown promising results in combination with other drugs.
6. TMC-207 (R207910): TMC-207 is a diarylquinoline that's being developed by Janssen Pharmaceuticals. It's in Phase II clinical trials for the treatment of MDR-TB and has shown promising results in combination with other drugs.
7. SQ109: SQ109 is a novel antibiotic being developed by the non-profit organization TB Alliance. It's in Phase II clinical trials for the treatment of MDR-TB and has shown promising results in combination with other drugs.

These new drugs and treatments offer hope for improving treatment outcomes for MDR-TB patients. However, more research is needed to fully understand their efficacy and safety, as well as to develop effective treatment regimens that combine these new drugs with existing ones.

It's worth noting that the development of new TB drugs is a complex and challenging process, requiring significant investment and collaboration between governments, non-profit organizations, and pharmaceutical companies.